Propionic acidemia is a rare, inherited metabolic disorder in which the body cannot properly break down certain proteins and fats, leading to a dangerous buildup of propionic acid and related compounds in the blood. It follows an autosomal recessive inheritance pattern, meaning a child must receive a faulty gene copy from each parent, and it results from mutations in either of the two genes that encode the enzyme propionyl-CoA carboxylase. Treatment has historically centered on strict dietary protein restriction and emergency protocols during metabolic crises, but liver transplantation and, more recently, mRNA-based therapies are shifting what is possible for affected families.
The Enzyme at the Center of the Problem
Propionyl-CoA carboxylase, or PCC, is the enzyme that converts propionyl-CoA into methylmalonyl-CoA, one step in the pathway that breaks down certain amino acids and odd-chain fatty acids so the body can use them for energy.1PubMed Central. Propionyl-CoA carboxylase – A review When PCC does not work properly, propionyl-CoA and its byproducts accumulate. Research suggests these metabolites impair the energy-producing machinery inside mitochondria and trigger oxidative stress, which damages cells throughout the body.2PubMed Central. Pathophysiological mechanisms of complications associated with propionic acidemia That cellular damage is why propionic acidemia does not just cause metabolic crises but also harms the brain, heart, kidneys, and bone marrow over time.
Genetics and Inheritance
PCC is built from two different protein subunits, called alpha and beta. The alpha subunit is encoded by the PCCA gene (on chromosome 13), and the beta subunit is encoded by the PCCB gene (on chromosome 3). Mutations in either gene can cause propionic acidemia.3PubMed. Overview of mutations in the PCCA and PCCB genes causing propionic acidemia Because inheritance is autosomal recessive, both copies of the affected gene must carry a pathogenic variant for the disease to manifest.4Molecular Genetics and Metabolism. Propionic acidemia: mutation update and functional and structural effects of the variant alleles Carriers who have just one faulty copy are unaffected.
Dozens of different mutations have been identified in both genes, and the mix varies considerably by population. A study of Indian patients found that the majority of mutations occurred in the PCCA gene, with 20 distinct PCCA mutations and 6 in PCCB among 25 patients.5PubMed. Seventeen Novel Mutations in PCCA and PCCB Genes in Indian Propionic Acidemia Patients, and Their Outcomes In Saudi Arabia, however, a single missense variant in PCCA accounted for about 70% of affected families and was associated with severe disease, suggesting it likely originated from a common ancestor in that population.6PubMed Central. Spectrum of mutations underlying Propionic acidemia and further insight into a genotype-phenotype correlation for the common mutation in Saudi Arabia
One of the most striking population-level findings involves the Inuit population of Greenland, where researchers discovered a carrier frequency of about 1 in 20 for a specific 3-base-pair insertion in the PCCB gene. That is extraordinarily high compared with carrier rates for most autosomal recessive diseases, and the mutation appears to be a founder variant that spread through a relatively small and isolated population.7PubMed Central. High incidence of propionic acidemia in greenland is due to a prevalent mutation, 1540insCCC, in the gene for the beta-subunit of propionyl CoA carboxylase These population-specific founder mutations are one reason incidence rates for propionic acidemia vary widely around the world, with much higher rates in regions where consanguinity is common or genetic bottlenecks occurred historically.
Early-Onset Versus Late-Onset Disease
Propionic acidemia generally splits into two clinical forms based on when symptoms first appear. In the early-onset form, which accounts for the large majority of cases, babies become sick within the first days to weeks of life. Roughly 80% of patients show symptoms during the neonatal period, with poor feeding, vomiting, lethargy, and seizures as the hallmark signs. Blood tests at this stage typically reveal severe metabolic acidosis, high ammonia levels, and elevated ketones.8Pediatric Academy Case Reports. A case of propionic acidemia during late infancy presenting with metabolic acidosis Without rapid intervention, neonatal-onset disease can be fatal. A retrospective review of 20 patients found that those presenting in the first week of life had a far higher death rate than those diagnosed later.9Pediatric Neurology. Neurologic outcome of propionic acidemia
Late-onset propionic acidemia is more variable. Some children are not diagnosed until infancy or even later childhood, often after an illness or dietary change triggers an episode of metabolic acidosis. Symptoms in this group may include developmental delays, low muscle tone, movement abnormalities, and recurrent infections.8Pediatric Academy Case Reports. A case of propionic acidemia during late infancy presenting with metabolic acidosis The late-onset form tends to have a better survival outlook, but severe movement disorders, including chorea and dystonia, were actually more prominent in the late-onset group in the same retrospective review.9Pediatric Neurology. Neurologic outcome of propionic acidemia
Neurological Complications
The brain is one of the organs most vulnerable to the toxic effects of propionic acid accumulation. Neurological complications span a wide range: developmental delay, intellectual disability, seizures, optic nerve problems, cranial nerve abnormalities, and metabolic stroke-like episodes.10PubMed. Neurologic considerations in propionic acidemia One particularly worrying finding is that intellectual impairment appears common even in children who have been well managed since birth. A study of children diagnosed in the neonatal period found that all had some degree of intellectual impairment, including two patients who had experienced no significant episodes of high ammonia and had grown normally since their initial crisis.11PubMed. Neonatal-onset propionic acidemia: neurologic and developmental profiles, and implications for management
Metabolic strokes deserve special mention because they can occur even outside of obvious metabolic crises. Imaging of the brain during or after these events often shows changes in the basal ganglia, the deep brain structures involved in movement. In some patients, these signal abnormalities appeared on MRI years after the original episode, and the stroke-like events happened without the usual laboratory signs of metabolic decompensation.12PubMed Central. Metabolic Strokes in Propionic Acidemia: Transient Hemiplegic Events Without Encephalopathy This observation complicates clinical management considerably, because families and physicians cannot rely on blood markers alone to catch every neurological event.
Cardiac, Renal, and Blood-Related Complications
Propionic acidemia is not just a brain disease. The heart is increasingly recognized as a major organ at risk. An observational study of 18 patients found that about 39% developed reduced heart pumping function (systolic dysfunction), typically in the teenage years, and about 61% showed abnormalities in how the heart relaxes between beats (diastolic dysfunction), which often preceded the more severe pumping problems.13PubMed. Cardiac phenotype in propionic acidemia – Results of an observational monocentric study There have also been reports of prolonged QT intervals on electrocardiograms, a heart-rhythm abnormality that can predispose to dangerous arrhythmias.14PubMed. Coincidence of long QT syndrome and propionic acidemia Regular cardiac screening is now a standard recommendation for all people with propionic acidemia.
Kidney disease is another long-term concern. A study of adult patients found an unexpectedly high prevalence of chronic kidney disease, with half of the adults showing estimated kidney filtration rates below the threshold that defines kidney disease. The decline appeared to be progressive and likely involves ongoing damage to the kidney tubules, though the exact mechanisms are still being worked out.15PubMed Central. Chronic Kidney Disease in Propionic Acidemia This is a finding that has changed how clinicians monitor adult patients, since kidney function had not historically been a primary focus.
Blood cell production can also take a hit. During acute crises, some patients develop pancytopenia, where counts of red cells, white cells, and platelets all drop. Research tracing this problem found that propionic acid itself directly inhibits the growth of blood cell precursors in the bone marrow, and the effect is concentration-dependent, meaning higher levels of circulating propionic acid cause more severe suppression.16PubMed. Pancytopenia in propionic acidemia: hematologic evaluation and studies of hematopoiesis in vitro Fortunately, the pancytopenia is usually reversible once the metabolic crisis is treated and propionic acid levels come back down.
Newborn Screening and Diagnosis
In many countries and U.S. states, propionic acidemia is part of standard newborn screening programs. The initial screen measures propionylcarnitine (C3) levels in a dried blood spot collected shortly after birth. Because elevated C3 can also signal methylmalonic acidemia and a few other conditions, some programs have added second-tier biochemical testing to improve specificity and reduce the number of false positives that trigger unnecessary alarm for families.17PubMed Central. Screening for Methylmalonic and Propionic Acidemia: Clinical Outcomes and Follow-Up Recommendations Confirmatory diagnosis requires urine organic acid analysis, plasma amino acid and acylcarnitine profiles, and ultimately genetic testing to identify which gene is mutated. The speed of diagnosis matters enormously: the sooner dietary and medical management begins, the better the chances of preventing the worst outcomes of the first metabolic crisis.
Dietary Management
The cornerstone of day-to-day treatment is limiting the amino acids that generate propionyl-CoA when broken down. In practice this means restricting natural protein intake, since the offending amino acids (isoleucine, valine, methionine, and threonine) are found in virtually all protein-containing foods. But total restriction is not the goal. Children still need enough protein to grow and develop, so the approach is to provide a carefully calculated amount of natural protein supplemented by specially formulated medical foods that supply the amino acids patients can safely metabolize.
Long-term dietary tracking has shown that natural protein intake in propionic acidemia patients typically runs at about 60–80% of the recommended daily allowance for age, while total protein intake (natural protein plus medical formula) often exceeds 100% of recommended levels, particularly in younger children. The average contribution from medical formula in one longitudinal study was roughly equal to the natural protein intake itself.18PubMed Central. Long term follow-up of the dietary intake in propionic acidemia This balancing act requires ongoing monitoring by a metabolic dietitian, and prescriptions change as a child grows, becomes more active, or gets sick.
Additional dietary strategies include ensuring adequate calorie intake from carbohydrates and fats so the body does not break down its own muscle protein for energy, which would release more of the problematic amino acids. During illnesses, even mild ones, caloric support becomes especially important to prevent the catabolic spiral that triggers metabolic crises.
Reducing Gut Bacterial Propionate
Gut bacteria are an often-overlooked source of propionic acid. Some intestinal bacteria produce propionate as a normal byproduct of fermenting dietary fiber and other substrates. In healthy people this is harmless and even beneficial, but in someone with propionic acidemia, every additional source of propionate matters. Studies have measured at least a 22% reduction in total propionate production after a course of the antibiotic metronidazole, suggesting that gut bacteria contribute a meaningful fraction of the overall propionate load.19Metabolism. Sources of propionate in inborn errors of propionate metabolism
Because of this, intermittent or rotating antibiotic courses have become part of standard chronic management, though the evidence supporting long-term benefit remains limited. European guidelines note that metronidazole at standard pediatric doses has been widely used for this purpose, but caution is warranted because of side effects including QT prolongation and pancreatitis. If metronidazole is not tolerated, alternatives such as amoxicillin or cotrimoxazole have been used.20PubMed Central. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision
Interestingly, research into the gut microbiome of propionic acidemia patients has revealed broader changes beyond just propionate-producing bacteria. Compared with healthy controls, patients showed lower levels of beneficial butyrate-producing bacteria such as Roseburia and Faecalibacterium, increased levels of Proteobacteria, and reduced overall microbial diversity and stability.21PubMed Central. Altered gut microbiome diversity and function in patients with propionic acidemia Whether these microbiome shifts are a consequence of the restricted diet, the antibiotic courses, the disease itself, or some combination is still an open question.
Emergency Management of Metabolic Crises
Even with careful dietary management, metabolic decompensation episodes remain a constant threat. Infections, fevers, surgery, fasting, or even emotional stress can tip the balance toward catabolism, flooding the body with propionyl-CoA it cannot process. The immediate priorities during a crisis are stopping all protein intake temporarily, providing high-calorie intravenous fluids (primarily glucose) to halt protein breakdown, correcting acidosis and electrolyte imbalances, and aggressively treating any underlying infection. Expert consensus recommendations emphasize that initial management is critical for preventing death and long-term damage, and patients who present at hospitals without metabolic expertise should be transferred to a specialized center as quickly as possible.22PubMed Central. Acute management of propionic acidemia
Carnitine supplementation is another standard component of both emergency and chronic management. Carnitine helps bind and excrete excess propionyl groups through the urine as propionylcarnitine, effectively acting as a detoxification shuttle. Ammonia-lowering agents may be needed if hyperammonemia is severe, since very high ammonia levels can cause brain swelling and permanent injury independently of the acidosis itself.
Liver Transplantation
For patients who experience frequent metabolic crises despite optimal dietary and medical management, liver transplantation has emerged as a meaningful therapeutic option. The liver is a major site of PCC enzyme activity, so replacing it provides a partial enzymatic correction. A systematic review and meta-analysis found a pooled metabolic stability rate of about 98% after transplant, and other disease complications such as kidney dysfunction and cardiomyopathy stabilized or improved in transplanted patients.23PubMed. Liver Transplantation for Propionic Acidemia: Evidence From a Systematic Review and Meta-analysis 24Liver Transplantation. Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes
However, liver transplant is not a cure. PCC is expressed in tissues throughout the body, not just the liver, so the brain, heart, and kidneys remain vulnerable to ongoing low-level toxicity from locally produced metabolites. A survival analysis of 94 transplanted patients estimated a survival probability of about 62% at age 33 and a median survival around 40 years, which represents a substantial deficit compared with the general population.25PubMed Central. Survival of propionic acidemia patients with liver transplant Fatal metabolic strokes have been documented years after transplant, underscoring that the neurological risk persists even when metabolic crises become less frequent.26PubMed. Fatal metabolic stroke in a child with propionic acidemia 11 years post liver transplant
The decision to transplant involves weighing the risks of major surgery, lifelong immunosuppression, and possible organ rejection against the potential reduction in crisis frequency and improvement in quality of life. Transplant does ease the dietary restrictions and reduces the constant anxiety over metabolic decompensation, which for many families is itself a significant quality-of-life gain. But the long-term cardiac, renal, and neurological surveillance continues after transplant just as before.
mRNA Therapy and the Next Generation of Treatment
Perhaps the most exciting recent development is the emergence of mRNA-based enzyme replacement therapy. The concept is straightforward: deliver mRNA encoding both the PCCA and PCCB subunits into liver cells, where the cell’s own machinery translates the mRNA into functional PCC enzyme. Preclinical work in a mouse model of propionic acidemia showed that lipid nanoparticles loaded with dual mRNAs restored PCC expression in the liver to near-normal levels after a single intravenous dose, and repeated dosing over months produced sustained reductions in toxic metabolites with no observed adverse effects.27PubMed Central. mRNA-based enzyme replacement for propionic acidaemia
These results led to a first-in-human clinical trial of a product called mRNA-3927. Interim results from the phase 1/2 trial showed dose-dependent increases in exposure and, among the eight participants who had experienced metabolic crises in the year before treatment, a roughly 70% reduction in the risk of metabolic decompensation events.28Nature. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia The trial is still ongoing, and longer follow-up is needed to understand durability, optimal dosing, and whether the treatment can slow or prevent the cardiac and neurological complications that define the disease’s long-term trajectory. But for a condition that has had essentially the same management toolkit for decades, even preliminary data this encouraging has generated real optimism among both clinicians and patient families.
One important nuance: mRNA therapy, like liver transplant, delivers enzyme primarily to the liver. Whether it can meaningfully reduce toxic metabolite levels in the brain or heart remains an open question. The blood-brain barrier limits what large molecules can reach neural tissue, so neurological protection may require different delivery strategies or complementary approaches. Still, if mRNA therapy can dramatically reduce the frequency and severity of metabolic crises and ease the restrictive diet, it would represent a major step forward even without solving every aspect of the disease.
The Gut Microbiome as an Emerging Research Front
Beyond its role as a propionate source, the gut microbiome in propionic acidemia patients has become a subject of active investigation for what it might reveal about the disease’s systemic effects. The depleted butyrate-producing bacteria found in patients are normally considered protective for the intestinal lining, and butyrate itself was particularly low in the most severely affected patient group.21PubMed Central. Altered gut microbiome diversity and function in patients with propionic acidemia This raises the possibility that the gut itself may be a site of chronic low-grade inflammation or barrier dysfunction in these patients, which could contribute to systemic complications in ways that are not yet well characterized. Whether targeted probiotic or prebiotic interventions could help restore a healthier microbial balance without increasing propionate production is a question researchers are beginning to explore, though no clinical trials have yet tested this directly in propionic acidemia.